Market Update

22 November 2023

NZX/ASX Code: EBO

Market Update


EBOS Group Limited (EBOS) advises that it has recently been engaged in discussions regarding a
potential strategic transaction related to its Animal Care segment. These discussions have now
concluded and a transaction will not proceed.

Trading update

EBOS has had a pleasing start to the FY24 financial year and strong growth has continued following
the trading update provided at the Annual Meeting. YTD growth for the four months to 31 October
2023 compared to the prior corresponding period was as follows
1
:

YTD growth vs pcp Underlying
Normalised excluding
Chemist Warehouse
Australia contract
Normalised excluding
COVID-19 anti-viral
wholesale sales
Revenue 8.2% 8.0% 10.1%
EBITDA 8.8% ~10% ~10%


Authorised for lodgement with NZX and ASX by the Board of EBOS Group Limited.

For further information please contact:
Martin Krauskopf
Executive General Manager, Strategy and Mergers & Acquisitions
+61 3 9918 5555
Martin.Krauskopf@ebosgroup.com


About EBOS Group
EBOS Group Limited NZBN 9429031998840 (NZX/ASX Code: EBO) is the largest and most diversified
Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical
products. It is also a leading Australasian animal care brand owner, product marketer and distributor.



1
FY24 year to date results are for the four months ended 31 October 2023 on an underlying basis and are based on
unaudited results. Underlying earnings exclude one-off items and amortisation (non-cash) expense attributable to the
LifeHealthcare acquisition purchase price accounting of finite life intangible assets.